Do Some People Never Test Positive for COVID?

Some people lived with a COVID-positive partner, shared a bed, and never once tested positive themselves. This is not merely anecdotal: researchers have been studying these “discordant” household contacts since early in the pandemic, and the evidence now points to several overlapping biological explanations for why a subset of heavily exposed people appear to dodge infection entirely. The reasons range from rapid-fire immune responses that snuff out the virus before it gains a foothold, to genetic variations in the very receptor the virus uses to enter cells, to something as mundane as taking a rapid test at the wrong moment.

The Testing Problem Comes First

Before assuming someone truly resisted infection, it is worth understanding how easy it is to get a false negative. Rapid antigen tests, the ones most people used at home, have a sensitivity of roughly 47% when measured against the gold-standard PCR test. That means they miss more than half of infections that PCR would catch.¹ The reason is straightforward: antigen tests need a certain viral load before they turn positive, and both the timing and the person’s biology affect that load.

Studies in children illustrate the timing issue well. On the actual day symptoms start, rapid antigen positivity can be as low as about 64%, jumping to nearly 95% a day later and reaching 100% on day two before declining again.² People who test once on the first day of exposure and call it done have a decent chance of missing an infection entirely. Those with low viral loads, whether due to partial immunity or individual biology, may never cross the threshold an antigen test requires. Even PCR, though far more sensitive, peaks at about 83% positivity around three days after symptom onset and misses infections outside that window.¹

So a portion of “never positive” people were actually infected but tested at the wrong time, tested only once, or had such low viral loads that neither their rapid test nor even a PCR would have flagged them. But that does not explain everyone. Researchers have specifically designed studies to exclude this possibility, recruiting people who were swabbed repeatedly over weeks while living with infected partners. Many of those people still showed no detectable virus at any point.

Abortive Infection and the Quick Kill

The concept that best explains genuine resistance is called abortive infection. In these cases, the virus enters the body, begins to interact with cells, and is then eliminated so rapidly by the immune system that it never replicates enough to show up on a test or trigger antibody production. The person was exposed and technically “infected” at the cellular level, but the virus hit a dead end.³

This concept got direct experimental support from human challenge trials, where healthy young volunteers were deliberately given a dose of SARS-CoV-2 through the nose. Of 34 seronegative volunteers, about half became infected while the rest did not. Among those who stayed uninfected, some showed fleeting traces of virus on PCR swabs that were low-level and never sustained, consistent with abortive infection rather than complete avoidance of viral contact.⁴ Their immune systems caught and killed the virus so fast it barely registered on even the most sensitive tests.

Researchers who tracked the immune responses of those challenge-trial participants found that the ones who fought off the virus showed a strong interferon-dominated response at the mucosal level, essentially in the nose and throat, with distinct timing compared to the systemic blood response.⁵ In plain terms: their nasal lining mounted a rapid antiviral defense before the virus could spread deeper into the body.

Prior Colds That Primed the Immune System

One of the more surprising findings from early pandemic research was that some people who had never been exposed to SARS-CoV-2 already had T cells capable of recognizing it. The explanation turned out to be cross-reactivity: their immune systems had previously fought off seasonal coronaviruses, the ones that cause common colds, and some of the T cells generated during those old infections happened to recognize parts of SARS-CoV-2 as well.

A study of close household contacts of confirmed COVID-19 patients found that those who stayed PCR-negative had significantly higher levels of a specific type of cross-reactive T cell, the kind that secretes a signaling molecule called IL-2, at their baseline blood draw. The presence of these pre-existing T cells was associated with remaining uninfected, with each increase in their frequency raising the odds of a negative PCR result.⁶

Separate research confirmed that these cross-reactive T cells are common in the general population and get activated during both SARS-CoV-2 infection and vaccination. One research team identified a specific piece of the spike protein that is shared across multiple coronaviruses, and showed that T cells targeting this region were recruited into the immune response after natural infection and after the first dose of mRNA vaccine, behaving like a secondary (memory) immune response rather than a first-time reaction.⁷ This cross-reactive priming may partly explain why some unvaccinated people appeared strangely resilient early in the pandemic, and why first-dose vaccine responses were sometimes faster than expected.

There is a caveat: the cross-reactivity is not universal across all coronavirus families. T cell epitopes that are conserved among more closely related coronaviruses reliably trigger cross-reactive responses, but the more distantly related the viruses are, the less predictable the cross-protection becomes.⁸ Having fought off a cold coronavirus is not a guaranteed shield against SARS-CoV-2, but it appears to give some people a meaningful head start.

Genetic Variations in the Virus’s Entry Point

SARS-CoV-2 enters human cells by latching onto a protein on the cell surface called ACE2. Not everyone’s ACE2 protein is identical. Natural genetic variations change the shape and stickiness of this receptor in subtle ways, and some of those variations make it harder for the virus to bind.

Researchers have catalogued ACE2 variants that are predicted to decrease the virus’s ability to attach. One variant in particular, D355N, was shown in lab and animal experiments to restrict the interaction between the spike protein and ACE2, limiting infection.⁹ Other protective variants include K31R and E37K, which showed decreased binding affinity for the spike protein in biochemical assays.¹⁰ On the flip side, variants like K26R and T92I increased binding, potentially making carriers more susceptible.

These ACE2 differences are individually rare, and their population-level impact on who gets COVID is probably small. But in the occasional person who carries a strongly protective variant, the virus may have a genuinely harder time gaining entry. It is one piece of a puzzle that also includes a completely different genetic factor: the HLA system.

HLA Genes and Asymptomatic Clearance

HLA genes control how your immune system presents pieces of viruses to T cells, essentially how it flags invaders. One large study found that a variant called HLA-B*15:01 was more than twice as common among people who stayed completely asymptomatic after confirmed SARS-CoV-2 infection (about 20%) compared to those who developed symptoms (about 9%).¹¹ The researchers’ explanation: people with this variant had T cells that could already recognize SARS-CoV-2 because of prior exposure to seasonal coronaviruses. Their immune systems mounted a fast, effective response before symptoms ever developed.

This finding blurs the line between “never testing positive” and “testing positive but never getting sick.” Some carriers of HLA-B*15:01 probably did get infected in a technical sense but cleared the virus so efficiently that they might have tested negative on a rapid test and assumed they dodged it entirely. The boundary between abortive infection and asymptomatic infection is genuinely fuzzy, and HLA genetics appear to be one of the factors that determines which side of that line someone falls on.

What Lives in Your Nose Matters

An unexpected player in COVID susceptibility is the community of bacteria living in your nasal passages. A recent study found that the nasal microbiome significantly affects the expression of ACE2 and TMPRSS2, the two key proteins the virus uses to enter cells. People with high densities of certain bacteria, including Staphylococcus aureus, had higher expression of these entry proteins, while those with high densities of a bacterium called Dolosigranulum pigrum had lower expression.¹²

In practical terms, the bacterial balance in your nose appears to partly determine how many “doors” the virus finds open when it arrives. The researchers suggested that modifying the nasal microbiome could potentially reduce COVID risk, though this has not been tested as an intervention in humans. It does raise the possibility that some of the variation in susceptibility we see across people has nothing to do with their immune systems or their genes, and everything to do with the microbial ecosystem that the virus encounters first.

The Blood Type Connection

Early in the pandemic, several studies reported that people with blood type O seemed to get COVID less often than those with types A, B, or AB. A large Canadian population-based study found that type O was associated with about a 12% lower risk of testing positive compared to all other blood types combined, and a similar reduction in severe illness or death.¹³ A Saudi Arabian cohort found a similar protective effect for type O and a notably increased risk for type B.¹⁴

The effect is real but modest. Having blood type O did not make anyone immune. The absolute risk difference in the Canadian study worked out to roughly 4 fewer infections per 1,000 people compared to other blood types.¹³ It is not the kind of thing that would make someone never test positive across years of pandemic exposure. But in combination with other favorable traits, it could nudge someone further toward the resistant end of the spectrum.

Truly Never Infected vs. Infected Without Knowing

One complication in this whole question is that many people who believe they were never infected actually were. Asymptomatic SARS-CoV-2 infection is common, and asymptomatic people can shed virus for weeks. One study found an asymptomatic child remained PCR-positive for 28 days without ever developing symptoms or abnormal imaging.¹⁵ These individuals would have tested positive if swabbed, but if they never had a reason to test, they would have believed they never caught it.

French household studies highlighted this gap from the other direction. Household contacts who were exposed to confirmed COVID cases sometimes remained completely seronegative, showing no antibodies in their blood, yet still had SARS-CoV-2-specific T cell responses against multiple viral proteins.¹⁶ Their immune systems had clearly encountered the virus and responded, but the encounter never produced detectable antibodies and would have been invisible to standard antibody testing. This is likely a signature of abortive infection: enough viral exposure to activate T cells but not enough sustained replication to trigger the full antibody response.

A prospective study that specifically recruited “discordant pairs,” where one household member got sick and the other did not, enrolled 95 recently-exposed contacts and tracked them to tease apart these different categories of resistance.¹⁷ The existence of this kind of research underscores that scientists take the phenomenon seriously. The question has moved beyond “does this happen?” to “what combination of factors explains it in each individual?”

Beliefs About Infection Do Not Match Reality

Surveys have revealed a striking disconnect between what people believe about their own COVID status and what testing shows. In one large UK survey, about a quarter of respondents believed they had already had COVID, but only 4% had actually received a positive test.¹⁸ Those who believed they had been infected were less worried about COVID and less likely to follow public health measures, regardless of whether they had any confirmed evidence of past infection.

The mismatch runs in both directions. A French population study found that fewer than half of people who had positive antibody results (confirming past infection) actually reported having had COVID. Meanwhile, roughly half of people who self-reported having had the disease turned out to be antibody-negative.¹⁹ People rejected their own test results in both directions, either dismissing a negative as a false negative or ignoring a positive as irrelevant. If you know someone who swears they never caught COVID across three years of a pandemic, the honest answer is that they might be right, but they might also have had an infection so mild it was invisible to them.

The Role of Airway Immunity After Infection

One intriguing finding adds a twist to the resistance story. Researchers studying airway immunity found that more than 70% of people with mild or moderate COVID developed a specific type of autoantibody in their nasal passages after infection, targeting interferon-alpha. Counter-intuitively, these nasal autoantibodies were associated with better outcomes: fewer symptoms, stronger anti-viral immunity, and more efficient recovery.²⁰ This contrasts sharply with the well-known finding that pre-existing anti-interferon autoantibodies in the blood are linked to severe COVID.

The location matters enormously. In the blood, anti-interferon antibodies leave the body unable to mount a systemic antiviral response, which can be catastrophic. In the nose, transient anti-interferon antibodies produced after infection appear to help fine-tune the local immune response, preventing the kind of excessive inflammation that causes tissue damage. This finding is still new and the mechanisms are being worked out, but it hints at why some people’s nasal immune environments are better at handling SARS-CoV-2 than others, and why local airway immunity might be more important than blood-level immunity for determining who fights off the virus before it ever takes hold.

How All These Factors Stack Up

No single factor makes someone “immune” to COVID. Instead, the evidence points to a layered defense where each advantage makes infection a little less likely or a little more quickly resolved. Someone with a favorable HLA type, a protective ACE2 variant, a nasal microbiome that keeps viral entry proteins low, strong cross-reactive T cells from past colds, and a robust mucosal interferon response might genuinely clear the virus before it registers on any test. Remove a couple of those layers, and the same person might develop a mild case they barely notice. Remove most of them, and they get a full-blown symptomatic infection.

The layering effect also explains why the “resistant” person’s luck can change. New variants alter the spike protein enough to partially evade existing cross-reactive T cells. Age weakens cross-reactive immunity: the pool of pre-existing coronavirus-reactive T cells shrinks over time.⁷ Someone who sailed through three waves unscathed might finally catch a variant that happens to dodge their particular combination of defenses. The biology is probabilistic, not absolute, which is worth remembering the next time someone credits their resistance to a particular supplement or lifestyle choice.

1
MMWR Morbidity and Mortality Weekly Report. SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance — Respiratory Virus Transmission Network, November 2022–May 2023
2
Journal of Clinical Virology Plus. Clinical performance and virological characteristics of the Quick Chaser SARS-CoV-2 rapid antigen assay in symptomatic children
3
PubMed Central. Can T Cells Abort SARS-CoV-2 and Other Viral Infections?
4
Nature Medicine. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
5
Science Immunology. Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
6
Nature Communications. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts
7
PubMed Central. Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
8
PubMed Central. Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
9
PubMed Central. Susceptibilities of Human ACE2 Genetic Variants in Coronavirus Infection
10
Communications Biology. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2
11
PubMed. Genetic variant associated with absence of COVID-19 symptoms
12
PubMed Central. The nasal microbiome modulates risk for SARS-CoV-2 infection
13
PubMed Central. Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness: A Population-Based Cohort Study
14
PubMed Central. Correlation between ABO Blood Group Phenotype and the Risk of COVID-19 Infection and Severity of Disease in a Saudi Arabian Cohort
15
PubMed Central. Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2
16
PubMed Central. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
17
PubMed Central. Discordant Outcomes of SARS-CoV-2 Exposure in Household Contacts
18
PLOS ONE. The impact of believing you have had COVID-19 on self-reported behaviour: Cross-sectional survey
19
JAMA Internal Medicine. Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic
20
Science Translational Medicine. Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19